The BLOC1S4 Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of HT29 cells carrying targeted disruption of the BLOC1S4 gene. This product provides a loss-of-function model in which the BLOC1S4 protein, a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), is ablated. The polyclonal nature of the knockout population ensures genetic heterogeneity while maintaining uniform protein knockout, facilitating robust phenotypic analysis in a cancer-relevant background.
HT29 is a human colorectal adenocarcinoma cell line originally isolated from a 44-year-old female patient. These cells serve as an established in vitro model for intestinal epithelial biology, widely utilized to investigate colorectal cancer pathogenesis, epithelial barrier function, and cellular differentiation. HT29 cells retain key epithelial characteristics, including the ability to form polarized monolayers and express mucins, making them suitable for studying membrane trafficking and organelle dynamics in a malignant epithelial context.
BLOC1S4 encodes the subunit 4 of the BLOC-1 complex, which functions as an essential adaptor in endosomal sorting and targeting of cargo proteins to nascent lysosome-related organelles. The BLOC-1 complex interacts with the AP-3 complex, clathrin, and other BLOC-1 subunits including BLOC1S1, BLOC1S2, and BLOC1S3 to regulate the trafficking of melanosomal cargo such as TYRP1 and factors required for platelet dense granule biogenesis. Disruption of BLOC1S4 impairs BLOC-1 function, leading to defective biogenesis of melanosomes and other lysosome-related organelles, which is clinically associated with Hermansky-Pudlak syndrome type 7, oculocutaneous albinism, and bleeding disorders.
In the HT29 colorectal cancer epithelial background, loss of BLOC1S4 permits dissection of how endosomal trafficking and lysosome-related organelle formation influence malignant cell behavior. Given the dependence of cancer cell proliferation, migration, and drug resistance on intracellular trafficking pathways, this knockout model enables investigation into the role of BLOC-1-dependent trafficking in colorectal adenocarcinoma. Potential phenotypic outcomes include altered distribution of lysosomal and secretory organelles, which can be linked to changes in cell adhesion, migration, and sensitivity to chemotherapeutic agents.
This polyclonal BLOC1S4 knockout HT29 product is suitable for a wide range of applications, including mechanistic studies of endosomal trafficking in colorectal cancer, modeling of Hermansky-Pudlak syndrome type 7 cellular phenotypes, and interrogation of lysosome-related organelle biogenesis pathways. Experimentally, these cells can be employed in immunofluorescence to visualize organelle subcellular localization, Western blotting and RT-qPCR for expression analysis of cargo proteins like TYRP1, migration assays to assess metastatic potential, and drug sensitivity assays to evaluate therapeutic vulnerabilities. For additional information or technical support, please contact Ascent Research.
